Terapia skojarzona choroby Alzheimera – racjonalny wybór w umiarkowanym i ciężkim stadium otępienia Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 14, 2015
Słowa kluczowe:
choroba Alzheimera, inhibitory cholinesteraz, donepezyl, rywastygmina, galantamina, memantyna, terapia skojarzona
##plugins.themes.bootstrap3.article.main##
Abstrakt
Celem terapii objawowej w chorobie Alzheimera jest opóźnienie postępu zaburzeń poznawczych oraz zminimalizowanie zaburzeń behawioralnych. Lekami zarejestrowanymi w terapii otępienia alzheimerowskiego są inhibitory cholinesteraz (donepezyl, rywastygmina i galantamina) oraz memantyna. W poniższym artykule podsumowano argumenty uzasadniające stosowanie tych leków w skojarzeniu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sienkiewicz-Jarosz , H. (2015). Terapia skojarzona choroby Alzheimera – racjonalny wybór w umiarkowanym i ciężkim stadium otępienia . Medycyna Faktów , 8(3(28), 75-78. Pobrano z https://www.journalsmededu.pl/index.php/jebm/article/view/2300
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. World Health Organization and Alzheimer’s Disease International. Dementia: a public health priority. Geneva, Switzerland: World Health Organization. 2012.
2. Birks J.: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev. 2006: CD005593.
3. Parsons C.G., Danysz W., Dekundy A. et al.: Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox. Res. 2013; 24(3): 358-369.
4. McShane R., Areosa Sastre A., Minakaran N.: Memantine for dementia. Cochrane Database Syst. Rev. 2006: CD003154.
5. Danysz W., Parsons C.G.: Alzheimer’s disease, β-amyloid, glutamate, NMDA receptors and memantine – searching for the connections. Br. J. Pharmacol. 2012; 167(2): 324-352.
6. Neumeister K.L., Riepe M.W.: Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer’s disease. J. Alzheimers Dis. 2012; 30(2): 245-251.
7. Rammes G., Danysz W., Parsons C.G.: Pharmacodynamics of memantine: an update. Curr. Neuropharmacol. 2008; 6(1): 55-78.
8. Flirski M., Sobów T.: Memantyna i inhibitory cholinesteraz: terapia skojarzona choroby Alzheimera. Farm. Psych. Neurol. 2011; 2: 75-83.
9. Schmidt R., Hofer E., Bouwman F.H. et al.: EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur. J. Neurol. 2015; 22(6): 889-898.
10. Grossberg G.T., Manes F., Allegri R.: A multinational, randomized, double-blind, placebo-controlled parallel-group trial of memantine extended- release capsule (28 mg, once daily) in patients with moderate to severe Alzheimer’s disease. Alzheimers Dement. 2008; 4: T793.
11. Howard R., McShane R., Lindesay J. et al.: Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N. Engl. J. Med. 2012; 366: 893-903.
12. Tariot P.N., Farlow M.R., Grossberg G.T. et al.: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291(3): 317-324.
13. Porsteinsson A.P., Grossberg G.T., Mintzer J. et al.: Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr. Alzheimer Res. 2008; 5: 83-89.
14. Olin J.T., Bhatnagar V., Reyes P. et al.: Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int. J. Geriatr. Psychiatry 2010; 25: 419-426.
15. Howes L.G.: Cardiovascular effects of drugs used to treat Alzheimer’s disease. Drug Saf. 2014; 37(6): 391-395.
16. Hansen R.A., Gartlehner G., Webb A.P. et al.: Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin. Interv. Aging. 2008; 3(2): 211-225.
17. Lopez O.L., Becker J.T., Wahed A.S. et al.: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 2009; 80(6): 600-607.
18. Lachaine J., Beauchemin C., Legault M. et al.: Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Can. J. Psychiatry 2011; 56: 596-604.
19. Touchon J., Lachaine J., Beauchemin C. et al.: The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France. Eur. J. Health Econ. 2014; 15(8): 791-800.
20. Karlawish J.H., Klocinski J.L., Merz J. et al.: Caregivers’ preferences for the treatment of patients with Alzheimer’s disease. Neurology 2000; 55(7): 1008-1014.
21. Agüera-Ortiz L., Frank-García A., Gil P. et al.: Clinical progression of moderate-to-severe Alzheimer’s disease and caregiver burden: a 12-month multicenter prospective observational study. Int. Psychogeriatr. 2010; 22(8): 1265-1279.
22. Saint-Laurent Thibault C., Özer Stillman I., Chen S. et al.: Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer’s type in the US. J. Med. Econ. 2015: 1-14.
23. Pfeil A.M., Kressig R.W., Szucs T.D.: Alzheimer’s dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland. Swiss. Med. Wkly. 2012; 142: w13676.
2. Birks J.: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev. 2006: CD005593.
3. Parsons C.G., Danysz W., Dekundy A. et al.: Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox. Res. 2013; 24(3): 358-369.
4. McShane R., Areosa Sastre A., Minakaran N.: Memantine for dementia. Cochrane Database Syst. Rev. 2006: CD003154.
5. Danysz W., Parsons C.G.: Alzheimer’s disease, β-amyloid, glutamate, NMDA receptors and memantine – searching for the connections. Br. J. Pharmacol. 2012; 167(2): 324-352.
6. Neumeister K.L., Riepe M.W.: Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer’s disease. J. Alzheimers Dis. 2012; 30(2): 245-251.
7. Rammes G., Danysz W., Parsons C.G.: Pharmacodynamics of memantine: an update. Curr. Neuropharmacol. 2008; 6(1): 55-78.
8. Flirski M., Sobów T.: Memantyna i inhibitory cholinesteraz: terapia skojarzona choroby Alzheimera. Farm. Psych. Neurol. 2011; 2: 75-83.
9. Schmidt R., Hofer E., Bouwman F.H. et al.: EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur. J. Neurol. 2015; 22(6): 889-898.
10. Grossberg G.T., Manes F., Allegri R.: A multinational, randomized, double-blind, placebo-controlled parallel-group trial of memantine extended- release capsule (28 mg, once daily) in patients with moderate to severe Alzheimer’s disease. Alzheimers Dement. 2008; 4: T793.
11. Howard R., McShane R., Lindesay J. et al.: Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N. Engl. J. Med. 2012; 366: 893-903.
12. Tariot P.N., Farlow M.R., Grossberg G.T. et al.: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291(3): 317-324.
13. Porsteinsson A.P., Grossberg G.T., Mintzer J. et al.: Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr. Alzheimer Res. 2008; 5: 83-89.
14. Olin J.T., Bhatnagar V., Reyes P. et al.: Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int. J. Geriatr. Psychiatry 2010; 25: 419-426.
15. Howes L.G.: Cardiovascular effects of drugs used to treat Alzheimer’s disease. Drug Saf. 2014; 37(6): 391-395.
16. Hansen R.A., Gartlehner G., Webb A.P. et al.: Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin. Interv. Aging. 2008; 3(2): 211-225.
17. Lopez O.L., Becker J.T., Wahed A.S. et al.: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 2009; 80(6): 600-607.
18. Lachaine J., Beauchemin C., Legault M. et al.: Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Can. J. Psychiatry 2011; 56: 596-604.
19. Touchon J., Lachaine J., Beauchemin C. et al.: The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France. Eur. J. Health Econ. 2014; 15(8): 791-800.
20. Karlawish J.H., Klocinski J.L., Merz J. et al.: Caregivers’ preferences for the treatment of patients with Alzheimer’s disease. Neurology 2000; 55(7): 1008-1014.
21. Agüera-Ortiz L., Frank-García A., Gil P. et al.: Clinical progression of moderate-to-severe Alzheimer’s disease and caregiver burden: a 12-month multicenter prospective observational study. Int. Psychogeriatr. 2010; 22(8): 1265-1279.
22. Saint-Laurent Thibault C., Özer Stillman I., Chen S. et al.: Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer’s type in the US. J. Med. Econ. 2015: 1-14.
23. Pfeil A.M., Kressig R.W., Szucs T.D.: Alzheimer’s dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland. Swiss. Med. Wkly. 2012; 142: w13676.